Background {#Sec1}
==========

Over the last two decades, *Klebsiella pneumoniae*, one of the most common nosocomial pathogens, has accumulated many resistance mechanisms. After its first isolation in 1996, in the United States, carbapenem-resistant *Klebsiella pneumonaiae* (CR-*Kp*) strains have caused numerous outbreaks of nosocomial infections in the northeastern United States, Israel, Greece, and Italy, becoming a serious clinical issue in these areas \[[@CR1]--[@CR3]\].

CR-*Kp* isolates are spreading worldwide in an ongoing dynamic process, constituting a new global health threat. Infections related to this pathogen are associated with increased mortality, longer hospital and intensive care unit (ICU) stay, and consequent increased cost of care \[[@CR4], [@CR5]\].

Hospitalized patients with several comorbidities, poor functional status, and prior exposure to antibiotics are typically affected with such infections \[[@CR6]\]. Preventive strategies aimed at reducing the spread of CR-*Kp* in the ICU are essential in reducing the infection rate related to these bacteria, which are a serious challenge for ICU physicians due to the exiguous available therapeutic options \[[@CR7]--[@CR10]\]. CR-*Kp* has an extensive drug resistance phenotype, and even the use of rescue antimicrobials (i.e., tigecycline, aminoglycosides, colistin, and fosfomycin) is frequently associated with clinical failure. Furthermore, although several reports suggest that the combination of more than one in-vitro active drug may be superior to monotherapy, the percentage of clinical failure remains high \[[@CR11]--[@CR14]\]. Conversely, among new antimicrobials, the use of novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime--avibactam) is still poor and is associated with the rapid emergence of resistance during treatment \[[@CR15], [@CR16]\].

Recently, the association of two synergistic carbapenems (ertapenem plus either meropenem, doripenem, or imipenem), alone or combined with other antibiotics, has been proposed as rescue treatment for CR-*Kp* infections \[[@CR17]--[@CR19]\].

Such combination therapy was prompted by evidence that ertapenem has the least in-vitro activity against CR-*Kp* due to an increased affinity for carbapenemases. Its role, as a suicide antibiotic, would allow the most active carbapenems to express their stronger activity at the infection site. However, although the data are encouraging, they are limited to in-vitro studies, case reports, and short case series \[[@CR20], [@CR21]\].

In this two-center, matched case--control study we analyzed the clinical and microbiological outcomes of patients affected with severe CR-*Kp* infections treated with a double carbapenem (DC) regimen, including ertapenem, compared with a standard rescue antibiotic treatment (ST).

Methods {#Sec2}
=======

Patient population and study design {#Sec3}
-----------------------------------

This study was conducted in the general ICUs of two tertiary hospitals in Italy admitting approximately 1500 patients per year. We performed a retrospective 1:2 matched case--control analysis on data prospectively acquired from electronic ICU charts and computerized investigation of microbiology laboratory databases. Because of its observational, noninterventional design, the study was approved by the local ethics committees, which waived informed consent (approval numbers: UCSC14669/15; EC Palermo 2 n° 359/2015). Eligibility criteria were as follows: age ≥ 18 years; ICU admission between November 2012 and December 2015; documented CR-*Kp* invasive infection (i.e., pneumonia, bloodstream infection, complicated intra-abdominal, skin and soft tissue, and urinary tract infections); and targeted antibiotic therapy lasting ≥ 72 hours. Patients who received DC treatment, including ertapenem, were matched with those treated with other standard antibiotic combinations (ST). Matching was based on severity of illness as defined by the Simplified Acute Physiology Score (SAPS) II at ICU admission (within 5 points), and by the Sequential Organ Failure Assessment (SOFA) scores (within 2 points) upon diagnosis of infection \[[@CR22], [@CR23]\]. When multiple control candidates met the core matching criteria, the choice was based on ICU admission dates. Investigators were blinded to case outcomes during matching.

Treatment regimens {#Sec4}
------------------

Meropenem and ertapemen were administered every 8 hours and 12/24 hours, respectively, at a daily dose of 6 g and 2 g, respectively, adopting the extended infusion strategy (at least 3 hours) \[[@CR24]\]. Colistin was administered every 12 hours at a daily dose of 9 million international units (MIU), after a 9 MIU loading dose. Gentamicin was administered every 24 hours at a daily per-kilogram dose of 5/7 mg. Tigecycline was administered at 100 mg every 12 hours after a 200 mg loading dose. Dosages were not changed during continuous renal replacement therapy (CRRT), including the colistin total daily dose, and were reduced in the presence of renal failure (except for tigecycline). Aminoglycoside therapeutic drug monitoring (TDM) was performed routinely.

Definitions and outcomes {#Sec5}
------------------------

Ventilator-associated pneumonia (VAP), bloodstream infections (BSIs), intra-abdominal infections (IAIs), skin and soft tissue infections (SSTIs), urinary tract infections (UTIs), septic shock (SS) status, and acute respiratory distress syndrome (ARDS) were classified according to current guidelines \[[@CR25]--[@CR31]\]. The primary outcome end-point was 28-day mortality; secondary outcomes were clinical cure, microbiological eradication, duration of mechanical ventilation and of vasopressors, and 90-day mortality. Clinical cure was defined as the complete resolution of all signs and symptoms of the infection by the end of targeted therapy. Improvement or lack of progression of all abnormalities on chest radiographs was also required for VAP. Microbiological eradication was defined as the absence of the original pathogens from the culture of the specimens subsequently collected from the original site.

The empirical antimicrobial regimen (i.e., that used before in-vitro susceptibility data were available) was classified as inadequate when it did not include any agent displaying in-vitro activity against the isolated pathogen.

Clinical outcomes were independently evaluated by two physicians (GDP and GM) who were blinded to the type of treatment. When judgments were discordant (about 3% of patients), the reviewers reassessed the data and reached a consensus decision.

Microbiological analysis {#Sec6}
------------------------

Strains were identified to the species level with matrix-assisted laser desorption ionization-time-of-flight (MALDITOF) mass spectrometry (MS) (BrukerDaltonik or Vitek MS; bioMérieux, Marcy l'Etoile, France). The antibiotic susceptibility profiling of isolates was carried out with the Vitek 2 system (bioMérieux). Results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints. Minimum inhibitory concentrations (MICs) of colistin and tigecycline were also assessed with the Sensititre broth microdilution method (Trek Diagnostic Systems, Cleveland, OH, USA). The phenotypic detection of carbapenemase expression in isolates with MICs \> 1 mg/L for carbapenems was carried out according to EUCAST guidelines. Isolates screened as positive were further investigated by polymerase chain reaction to identify genes for class A carbapenemases (KPC and GES enzymes), class B metallo-β-lactamases (VIM, IMP, and NDM enzymes), and class D carbapenemases (OXA-23, OXA-24/40, OXA-48, OXA-51, OXA-55, OXA-58, and OXA-143) \[[@CR32]\].

Statistical analysis {#Sec7}
--------------------

The Kolmogorov--Smirnov test was used to evaluate the distribution of variables. Data with a nonnormal distribution were assessed with the Mann--Whitney test, and the median and selected centile (25th--75th) values are given. The data with a normal distribution were assessed with the Student's *t* test. Categorical variables are given as proportions, and were analyzed with the chi-square test or Fisher's exact test, as appropriate. *p* \< 0.05 was considered significant. The crude odds ratio (OR) and 95% CI were calculated for each variable. We included all variables in the multivariable logistic regression if they reached *p* ≤ 0.1 on univariate analysis. A stepwise selection procedure was used to select variables for inclusion in the final model. The Hosmer--Lemeshow goodness-of-fit test and receiver operating characteristic (ROC) curve analysis were used to assess the goodness of the logistic final model. The Kaplan--Meier method was used for the survival analysis. All statistical analyses were performed using SAS 9.4 software (SAS Institute Inc, Cary, NC, USA).

Results {#Sec8}
=======

Population characteristics and treatment {#Sec9}
----------------------------------------

During the study period, 243 patients with CR-*Kp* infection were identified. Among 72 potentially eligible case patients receiving a DC regimen including ertapenem, alone or in combination with another "in vitro active antibiotic" (mainly colistin), 24 patients were excluded (mainly because they were treated for less than 72 hours) and 48 patients were selected for the analysis (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). These patients were compared with 96 corresponding controls who received an ST regimen not including carbapenems, matched for SAPS II and SOFA scores (baseline characteristics presented in Table [1](#Tab1){ref-type="table"}).Table 1Demographic and clinical characteristics of the 144 patients with KPC *Kp* invasive infection included in the studyVariableNumber (%) of patients*p* valueDC group (*n* = 48)ST group (*n* = 96)Demographics and comorbidities Age (years), mean ± SD55.5 ± 1561.3 ± 120.06 Males35 (72.9)58 (60.4)0.19 CHF18 (37.5)27 (28.1)0.34 COPD11 (22.9)12 (12.5)0.17 CRF8 (16.7)7 (7.3)0.15 Diabetes17 (35.4)31 (32.3)0.85 CLD10 (20.8)8 (8.3)0.06 Neoplasm2 (4.2)12 (12.5)0.21 Immunosuppressive status19 (39.6)26 (27.1)0.18 ICU stay before infection (days), median (IQR)11 (4--24)7 (1-22.5)0.08 Duration of MV before infection (days), median (IQR)6 (1.5-15.5)5 (1--14)0.57 Duration of vasopressors before infection (days), median (IQR)3 (1--10)1.5 (0--6)0.11Presenting feature Medical admission25 (52.1)59 (61.5)0.37 Surgical admission18 (37.5)30 (31.3)0.28 Trauma admission5 (10.4)11 (11.5)0.92SAPS II score, median (IQR)44 (36--56)46 (36--57)0.56SOFA score at infection, median (IQR)9 (7--11)8 (6--10)0.33Septic shock on occurrence of infection36 (75)43 (44.8)**\<0.01**ARDS on occurrence of infection18 (37.5)23 (23.9)0.13CRRT on occurrence of infection20 (41.7)26 (27.1)0.13PCT on occurrence of infection (ng/ml), median (interval)6.1 (3.2--50.4)3.1 (0.8--5.9)**\<0.01**Type of infection Pneumonia25 (52.1)49 (51)0.95 IAI9 (18.7)10 (10.4)0.19 SSTI1 (2.1)11 (11.5)0.06 UTI3 (6.2)9 (9.3)0.75 CVC BSI8 (16.7)10 (10.4)0.42 Primary BSI6 (12.5)10 (10.4)0.92 Secondary BSI23 (47.9)26 (27.1)**0.02** Multiple site infection4 (8.2)3 (3.1)0.54Therapeutic aspects IIAT13 (27.1)40 (41.7)0.16 Overall duration of treatment (days), median (interval)17 (11.5--25.5)11.5 (7.5--15.5)**\<0.01**Clinical and microbiological outcome 28-day mortality14 (29.2)46 (47.9)**0.04** 90-day mortality24 (50)58 (60.4)0.31 Clinical cure30 (62.5)47 (48.9)0.17 Microbiological eradication^a^22 (50)31 (38.3)0.27 Duration of MV after infection (days), median (interval)14 (7.5--31)11.5 (7--19)0.16 Duration of vasopressors after infection (days), median (interval)10.5 (3.5--27.5)8 (4.5--12)0.19Data presented as *N* (%), unless otherwise indicated. Bold data are significant*IQR* interquartile range, *KPC Klebsiella pneumoniae* carbapenemase, Kp *Klebsiella pneumoniae*, *DC* double carbapenem, *ST* standard treatment, *SAPS* Simplified Acute Physiology Score, *SOFA* Sequential Organ Failure Assessment, *ICU* intensive care unit, *MV* mechanical ventilation, *ARDS* acute respiratory distress syndrome, *CRRT* continuous renal replacement therapy, *PCT* procalcitonin, *CHF* chronic heart failure, *COPD* chronic obstructive pulmonary disease, *CRF* chronic renal failure, *CLD* chronic liver disease, *IAI* intra-abdominal infection, *SSTI* skin and soft tissue infection, *UTI* urinary tract infection, *CVC* central vascular catheter, *BSI* bloodstream infection, *IIAT* initial inappropriate antimicrobial therapy^a^Microbiological outcome was analyzed in 125 patients: 44 patients (DC group) and 81 patients (ST group)

There were no significant between-cohort differences in terms of demographics, type of admission, presenting features, main comorbidities, and infection types. Duration of ICU stay and the use of mechanical ventilation and vasopressors before infection occurrence were similar in both groups. About 50% of the patients were affected with CR-*Kp* pneumonia: 51 patients were classified as VAP, and 23 patients as hospital-acquired pneumonia (HAP) requiring ICU admission due to respiratory failure. Septic shock upon occurrence of infection, along with secondary bacteremia and high procalcitonin levels, were significantly more frequent in patients receiving DC treatment. The overall duration of therapy was significantly longer in the DC group than in controls (17 days vs 11.5 days, *p* \< 0.01). Seven patients (4.9%) had multiple site infections, and the overall rate of initial inappropriate antibiotic therapy was less than 50% in both groups. Adjunctive nebulized colistin (2 MUI every 8 hours, via jet/ultrasonic nebulizers) was used in 32 patients with VAP (seven cases and 25 controls). No between-group differences were identified in terms of MV and vasopressor duration after infection. No adverse events potentially associated with the use of the DC regimen were observed in both centers.

In 23 patients (16%) the infection was polymicrobial (15 CR *Acinetobacter baumannii* isolates and eight CR *Pseudomonas aeruginosa* isolates), without statistically significant differences between the two groups. The rate of combination therapy including at least one other active antibiotic was higher in the DC group (72.9% vs 54.2%, *p* = 0.05): antibiotic association details for the DC and ST groups are presented in Table [2](#Tab2){ref-type="table"}.Table 2Therapeutic and microbiological details according to the type of treatmentVariableNumber (%) of patients*p* valueDC group (*n* = 48)ST group (*n* = 96)Polymicrobial infection6 (12.5)17 (17.7)0.57 CR *Acinetobacter baumannii*3 (6.25)12 (12.5)0.4 CR *Pseudomonas aeruginosa*3 (6.25)5 (5.2)0.89Combined targeted therapy35 (72.9)52 (54.2)**0.05** DC + colistin19 (39.6)--**--** DC + gentamicin8 (16.9)--**--** DC + tigecycline3 (6.25)--**--** DC + colistin + tigecycline2 (4.2)--**--** DC + colistin + gentamicin3 (6.25)--**--** Colistin + tigecycline--22 (22.9)**--** Colistin + gentamicin--13 (13.5)**--** Gentamicin + tigecycline--10 (10.4)**--** Colistin + tigecycline + gentamicin--7 (7.3)**--**Extensively drug-resistant strains^a^32 (66.7)31 (32.3)**\<0.01** Colistin MIC ≤ 2 μg/ml28 (58.3)64 (66.7)0.42 Gentamicin MIC ≤ 2 μg/ml15 (31.3)72 (75)**\<0.01** Tigecycline MIC ≤ 1 μg/ml^b^16 (47.1)58 (60.4)0.27 Suboptimal MIC values^c^10 (20.8)14 (14.6)0.5Bold data are significant*DC* double carbapenem, *ST* standard treatment, *CR* carbapenem resistant, *MIC* minimal inhibitory concentration^a^Strains resistant to at least one agent in all but two or fewer usually active antimicrobial categories^b^MIC values were available in 130 patients: 34 pts (DC group) and 96 patients (ST group)^c^Gentamicin (4 μg/ml), tigecycline (2 μg/ml)

More than 90% of detected *Kp* produced class A carbapenemases (KPC), while the rest of the isolates harbored genes for class B metallo-β-lactamases and class D carbapenemases (OXA-48). About 40% of the isolated CR-*Kp* was resistant to either colistin or tigecycline (colistin sensitivity: 58.3% in the DC group vs 66.7% in controls, *p* = 0.42; tigecycline: 47.1% in the DC group vs 60.4% in controls, *p* = 0.27). Gentamicin sensitivity was significantly lower in patients receiving the ST regimen compared with the DC group (75% vs 31.3%, *p* \< 0.01). Furthermore, 24 strains (16.7%) showed suboptimal MIC values for at least one rescue antimicrobial molecule (pharmacological and microbiological details presented in Table [2](#Tab2){ref-type="table"}).

Outcomes and predictors of mortality {#Sec10}
------------------------------------

Twenty-eight-day mortality was significantly higher in patients receiving ST compared with those who were treated with the DC regimen (47.9% vs 29.2%, *p* = 0.04). Despite a trend toward a better outcome in the DC group, the rates of clinical cure and microbiological eradication did not significantly differ between the groups. Overall, considering the 90-day mortality after infection, 50% of patients in the DC group were alive compared with 39.6% in controls, but despite such a reduction trend the difference was nonsignificant (Table [1](#Tab1){ref-type="table"}).

However, stratifying the population according to the pattern of microbiological resistance, we found that clinical cure and microbiological eradication associated with DC were significantly higher in patients infected with CR-*Kp* resistant to colistin (clinical cure: 13/20 (65%) vs 10/32 (31.3%), *p* = 0.03; microbiological eradication: 11/19 (57.9%) vs 7/27 (25.9%), *p* = 0.04). Clinical cure was also higher for strains resistant to both gentamicin and colistin (clinical cure: 6/12 (50%) vs 0/6 (0), *p* = 0.05; microbiological eradication: 6/11 (54.5%) vs 0/5 (0), *p* = 0.09). No significant between-group differences were found in patients with germs resistant to either gentamicin or tigecycline, or to both gentamicin and tigecycline and to both colistin and tigecycline. Five infections were due to pan-resistant strains (three pneumonia and two complicated intra-abdominal infections): these were treated with the DC regimen, with a 40% rate of clinical cure and microbiological eradication (2/5) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1**a** Clinical cure rate according to antibiotic resistance. \**p* = 0.03, \*\**p* = 0.05. **b** Microbiological eradication rate according to antibiotic resistance. \**p* = 0.04. *R* resistance, *DC* double carbapenem, *ST* standard treatment, *Coli* colistin, *Genta* gentamicin, *Tige* tigecycline

On univariate analysis (Table [3](#Tab3){ref-type="table"}), deceased numbers of patients had higher SAPS II and SOFA scores compared with survivors. Acute kidney injury requiring CRRT, polymicrobial infections, and inappropriate initial antimicrobial treatment occurred more frequently in patients who died. In multivariable logistic regression analysis, the DC regimen was the sole independent factor associated with 28-day survival, while higher SAPS II and SOFA score were significantly associated with mortality (Table [4](#Tab4){ref-type="table"}). The multivariate Cox-regression model showed 28-day survival to be associated with the DC regimen (OR 0.43, 95% CI 0.23--0.79), and the difference in survival between treatment groups was also found on Kaplan--Meier survival curve analysis (*p* = 0.02). Unfortunately, such survival benefit was not maintained at 90-day mortality (*p* = 0.08) (Fig. [2](#Fig2){ref-type="fig"}).Table 3Univariate analysis of factors associated with 28-day mortalityVariableNumber (%) of patientsUnivariate analysisAlive (*n* = 84)Deceased (*n* = 60)*p* valueOR (95% CI)Demographics and comorbidities Age (years)57.7 ± 1561.7 ± 10**0.081.02 (0.99--1.05)** Males58 (69.1)35 (58.3)0.190.63 (0.31--1.25) CHF24 (28.6)21 (35)0.411.34 (0.66--2.74) COPD14 (16.7)9 (15)0.790.88 (0.35--2.2) CRF8 (9.5)7 (11.7)0.681.25 (0.43--3.67) Diabetes25 (29.8)23 (38.3)0.281.47 (0.73--2.95) CLD8 (9.5)10 (16.7)0.211.9 (0.7--5.14) Neoplasm7 (8.3)7 (11.7)0.511.48 (0.48--4.38) Immunosuppressive status27 (32.1)18 (30)0.780.9 (0.44--1.85) ICU stay before infection (days), median (IQR)8.5 (1--21)8 (1--23)0.691 (0.98--1.01) Duration of MV before infection (days), median (IQR)6 (1--13.5)5.5 (0.5--15)0.791.01 (0.98--1.03) Duration of vasopressors before infection (days), median (IQR)2 (0--7.5)2 (0--7)0.680.99 (0.97--1.02)Presenting features, type of infection, and therapy Medical admission45 (53.6)39 (65)0.171.61 (0.81--3.18) Surgical admission29 (34.5)15 (25)0.220.63 (0.3--1.32) Trauma admission10 (11.9)6 (10)0.720.82 (0.28--2.4) SAPS II score, median (IQR)39 (34--50)55 (45.5--63)**\<0.011.07 (1.04--1.08)** SOFA score on occurrence of infection, median (IQR)8 (5--9)9 (8--11)**\<0.011.36 (1.17--1.57)** SS on occurrence of infection42 (50)37 (61.7)0.171.6 (0.82--3.16) ARDS on occurrence of infection21 (25)20 (33.3)0.281.5 (0.72--3.11) CRRT on occurrence of infection22 (26.2)24 (40)**0.081.88 (0.92--3.82)** PCT on occurrence of infection (ng/ml), median (interval)3.4 (0.71--7.5)4.3 (2.3--8.6)0.431 (0.99--1.01)Type of infection and therapy Pneumonia41 (48.8)33 (55)0.461.28 (0.66--2.49) IAI14 (16.7)5 (8.3)0.150.45 (0.15--1.34) SSTI8 (9.5)4 (6.7)0.550.67 (0.19--2.37) UTI6 (7.1)6 (10)0.541.44 (0.44--4.72) CVC BSI11 (13.1)7 (11.7)0.80.88 (0.32--2.41) Primary BSI9 (10.7)7 (11.7)0.861.1 (0.39--3.14) Secondary BSI30 (35.7)19 (31.7)0.610.83 (0.41--1.69) Polymicrobial infection8 (9.5)15 (25)**0.013.17 (1.25--8.06)** Double carbapenem therapy34 (40.5)14 (23.3)**0.030.45 (0.21--0.94)** IIAT26 (30.9)27 (45)**0.081.82 (0.92--3.63)** Combination targeted therapy48 (57.1)39 (65)0.341.39 (0.7--2.76) Duration of active treatment (days), median (IQR)14 (8--18.5)10 (8--14.50.130.96 (0.93--1.01)Data presented as *N* (%), unless otherwise indicated. Bold data are significant*OR* odds ratio, *IQR* interquartile range, *SAPS* Simplified Acute Physiology Score, *SOFA* Sequential Organ Failure Assessment, *ICU* intensive care unit, *MV* mechanical ventilation, *SS* septic shock, *ARDS* acute respiratory distress syndrome, *CRRT* continuous renal replacement therapy, *PCT* procalcitonin, *CHF* chronic heart failure, *COPD* chronic obstructive pulmonary disease, *CRF* chronic renal failure, *CLD* chronic liver disease, *IAI* intra-abdominal infection, *SSTI* skin and soft tissue infection, *UTI* urinary tract infection, *CVC* central vascular catheter, *BSI* bloodstream infection, *IIAT* initial inappropriate antimicrobial therapy Table 4Multivariable logistic regression analysis of factors associated with 28-day mortalityVariable*p* valueOR (95% CI)SAPS II score\<0.011.08 (1.04--1.23)SOFA score≤0.011.36 (1.33--1.63)Double carbapenem treatment0.020.33 (0.13--0.87)We included all variables in the multivariable logistic regression if they reached *p* ≤ 0.1 on univariate analysis. A stepwise selection procedure was used to select variables for inclusion in the final modelROC curve analysis was used to assess the goodness of the final logistic regression model (AUC ± SE = 0.85 ± 0.034 with 95% CI 0.78--0.91; chi-square statistics *p* \< 0.001)*AUC* area under the curve, *OR* odds ratio, *ROC* receiver operating characteristic, *SAPS* Simplified Acute Physiology Score, *SOFA* Sequential Organ Failure Assessment, *SE* standard error Fig. 2Kaplan--Meier curves showing the impact of DC therapy (*black line*) versus ST (*gray line*) on **a** 28-day mortality and **b** 90-day mortality. *DC* double carbapenem, *ST* standard treatment

Discussion {#Sec11}
==========

In this population of critically ill patients affected with severe invasive infections due to carbapenem-resistant *Klebsiella pneumoniae*, the use of a DC regimen including ertapenem reduced 28-day mortality. Furthermore, clinical cure and microbiological eradication were more frequent in patients treated with the DC for colistin-resistant CR-*Kp* infections. Our findings support recent data suggesting the clinical efficacy of a DC regimen for the treatment of CR-*Kp* infections \[[@CR21], [@CR33]\].

*Kp*-producing carbapenemases are resistant to all beta-lactams, and to most aminoglycosides, fluoroquinolones, and sulphonamides \[[@CR9]\]. The few remaining options are colistin, tigecycline, fosfomycin, and gentamicin, which usually harbor high MIC values, and share a suboptimal pharmacokinetic profile in terms of distribution at many infection sites \[[@CR7], [@CR13], [@CR34]\]. Nonetheless, the use of gentamicin and colistin is frequently limited due to the risk of renal toxicity, and experience with the novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime--avibactam) in this setting is exiguous \[[@CR16]\]. The rationale behind the usefulness of a DC regimen is intriguing: ertapenem, binding with high affinity to the active site of *Kp* carbapenemase, would be able to prevent the hydrolysis of the coadministered drug (i.e., meropenem, imipenem, or doripenem), which may preserve its bactericidal activity against the infecting isolate \[[@CR35]\]. Indeed, carbapenemase consumption by ertapenem means that a high concentration of the associated drug can be active in the infection site, where a lower amount of carbapenemases will be available to degrade the administered antibiotic.

The preliminary observation of DC efficacy by Bulik and Nicolau in 2011 \[[@CR18]\] was confirmed by clinical experiences documenting the efficacy of the DC regimen, including ertapenem plus meropenem or doripenem, in patients treated for CR-*Kp* infections \[[@CR19]--[@CR21], [@CR33], [@CR36], [@CR37]\]. Recently a large series by Souli et al. \[[@CR19]\] reported encouraging data on the use of a DC regimen as the exclusive therapy for extensively or pan-drug-resistant CR-*Kp*, further summarizing the actual clinical evidence in the field. In their cohort, a relevant clinical success was reached (77.8%), and also in the pan-resistant group the clinical and microbiological success was comparable (78.5%). In their review of the literature, a trend toward DC efficacy was highlighted, although there were some discrepancies among series.

In our study, we aimed at enhancing such evidence by comparing a larger cohort of DC-treated patients with a matched cohort of similar patients.

Given residual antimicrobial susceptibility, more than half of our patients receiving DC (35 \[72.9%\]) were treated with another active drug, mainly colistin. This approach is reasonable, and recent data suggest that the coadministration of colistin may increase the in-vivo and in-vitro activity of DC, and should be preferred in critically ill patients where an early clinical response is warranted \[[@CR33], [@CR38]\]. Similarly, in line with expert opinion, 52 of 96 controls were managed with a combined targeted therapy \[[@CR39]--[@CR41]\]. A carbapenem-sparing regimen has been proposed by Sbrana et al. \[[@CR39]\], observing that the administration of tigecycline plus gentamicin or colistin was effective for the treatment of 24 CR-*Kp* infections in trauma patients, with a 14% mortality rate, further suggesting the usefulness of this approach when tigecycline is administered at a higher than standard dose (i.e., 50 mg every 12 hours after a 100 mg loading dose) \[[@CR42]\]. On the other hand, recent data advocate the efficacy of combining high dosages of meropenem with colistin or tigecycline for the treatment of *Acinetobacter* infections \[[@CR41]\]. These antibiotic associations have been seen to reduce mortality in patients with life-threatening infections due to extensively drug-resistant *Acinetobacter* and *Klebsiella*, but the benefits of meropenem can be expected only in the presence of MIC values close to susceptibility breakpoints. This kind of effect did not seem to have influenced the outcome of our cohort treated with DC because all of the strains were resistant to meropenem. In any event, we also have to address the idea of limiting the use of colistin in settings where KPC infections are frequent, given the alarming increase of colistin resistance in high-endemicity areas \[[@CR43], [@CR44]\].

Of note, we found a longer duration of antibiotic therapy in the DC group: such a result may be interpreted in light of the clinical profile of the DC group, in which patients, despite a higher percentage of septic shock, bacteremia rate, and PCT levels, showed higher survival together with a longer period of ICU support.

Moreover, the discrepancy in the effect of DC therapy between 28-day and 90-day mortality may be explained by the higher clinical impact of the septic episode on the short-term outcomes, along with the role of potential unmeasured confounders that may have influenced the 90-day mortality.

Our study has several limitations. First, although both centers adopted an electronic medical record, due to the observational nature we cannot exclude that unmeasured confounders may have influenced the strong association between DC use and improved survival. Second, synergistic assays for confirming DC in-vitro efficacy were not done routinely, although CR-*Kp* strains were studied according to genetic testing. Third, we did not check plasmatic carbapenem concentrations, so we can only assume that by optimizing dosages and administration modalities we achieved bactericidal meropenem levels at the infection site. Fourth, due to the use of the Vitek system, we cannot exclude that a small proportion of strains could display meropenem MIC values closer to the susceptibility breakpoint. Finally, we did not use either fosfomycin or ceftazidime--avibactam \[[@CR45]\] because both molecules were not available at our centers during the observation period.

Nonetheless, this is the largest observational study in critically ill patients in whom the use of DC was evaluated, and the first investigation in which such a strategy is compared with other rescue treatments (i.e., colistin, tigecycline, gentamicin), after matching for severity of the disease.

Conclusion {#Sec12}
==========

In the daily challenge of managing critically ill patients with CR-*Kp* infections, therapeutic options are limited. This observational analysis shows that the association of ertapenem plus meropenem provides a survival benefit, particularly when colistin cannot be used. Larger prospective studies are needed to confirm these findings, and to define the role of this unconventional strategy.
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Additional file 1:**Figure S1** showing a flow chart of the study inclusion process. *CR-*Kp carbapenem-resistant *Klebsiella* pneumoniae, *DC* double carbapenem, *ST* standard treatment. (PDF 92.6 kb)

ARDS

:   Acute respiratory distress syndrome

BSI

:   Bloodstream infection

CR-*Kp*

:   Carbapenem-resistant *Klebsiella pneumoniae*

CRRT

:   Continuous renal replacement therapy

DC

:   Double carbapenem

EUCAST

:   European Committee on Antimicrobial Susceptibility Testing

HAP

:   Hospital-acquired pneumonia

IAI

:   Intra-abdominal infection

ICU

:   Intensive care unit

MALDITOF

:   Matrix-assisted laser desorption ionization-time-of-flight

MIC

:   Minimum inhibitory concentration

MS

:   Mass spectrometry

OR

:   Odds ratio

ROC

:   Receiver operating characteristic

SAPS

:   Simplified Acute Physiology Score

SOFA

:   Sequential Organ Failure Assessment

SS

:   Septic shock

SSTI

:   Skin and soft tissue infection

ST

:   Standard treatment

TDM

:   Therapeutic drug monitoring

UTI

:   Urinary tract infection

VAP

:   Ventilator-associated pneumonia
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